Azopt (brinzolamide)
- Region
- 🇪🇺 EU
- Active substance
- brinzolamide
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Glaucoma, Open-Angle; Ocular Hypertension
- EU approval
- Thu 09 Mar 2000
- Application
- EMEA/H/C/000267
- ATC
- S01EC04
- Official record
- www.ema.europa.eu
Indication
Azopt is indicated to decrease elevated intraocular pressure in: ocular hypertension; open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Azarga Authorised · Novartis Europharm Limited
- 🇪🇺 Simbrinza Authorised · Novartis Europharm Limited
Follow Azopt
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.